Literature DB >> 9462905

Corticosteroids and neonatal chronic lung disease.

E Bancalari1.   

Abstract

UNLABELLED: There is increasing evidence that inflammation plays an important role in the pathogenesis of chronic lung disease (CLD). Systemic steroid administration reduces the concentration of inflammatory markers in tracheobronchial secretions and produces a rapid improvement in pulmonary compliance and resistance and an improvement in gas exchange in ventilator dependent infants. This improvement in lung function allows a reduction in ventilator settings and facilitates weaning from mechanical ventilation and increased inspired oxygen concentrations. Despite this rapid improvement in lung function, the use of steroids does not modify mortality or long-term outcome and it is associated with many acute side-effects and possible long-term deleterious consequences on lung and CNS development. Inhaled steroids have also been used in infants with CLD or at risk of CLD and although the reported side-effects are significantly less than with systemic therapy their effectiveness is also less obvious.
CONCLUSION: Steroid therapy in ventilator dependent infants reduces the duration of mechanical ventilation and oxygen therapy and may reduce the incidence of severe CLD. The use of steroids in infants with CLD does not improve survival rate or long-term neurological outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462905     DOI: 10.1007/pl00014290

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

Review 1.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

2.  Activation of nuclear factor kappaB and induction of inducible nitric oxide synthase by Ureaplasma urealyticum in macrophages.

Authors:  Y H Li; Z Q Yan; J S Jensen; K Tullus; A Brauner
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Prevention of bronchopulmonary dysplasia.

Authors:  Matthew M Laughon; P Brian Smith; Carl Bose
Journal:  Semin Fetal Neonatal Med       Date:  2009-09-06       Impact factor: 3.926

4.  Early prophylactic inhaled beclomethasone in infants less than 1250 g for the prevention of chronic lung disease.

Authors:  K A Jangaard; D A Stinson; A C Allen; M J Vincer
Journal:  Paediatr Child Health       Date:  2002-01       Impact factor: 2.253

5.  Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia.

Authors:  Kristen Tropea; Helen Christou
Journal:  Int J Pediatr       Date:  2012-01-03

Review 6.  Neonate Bloodstream Infections in Organization for Economic Cooperation and Development Countries: An Update on Epidemiology and Prevention.

Authors:  Jadwiga Wójkowska-Mach; Agnieszka Chmielarczyk; Magdalena Strus; Ryszard Lauterbach; Piotr Heczko
Journal:  J Clin Med       Date:  2019-10-21       Impact factor: 4.241

7.  Activation of macrophage nuclear factor-kappa B and induction of inducible nitric oxide synthase by LPS.

Authors:  Ying-Hua Li; Zhong-Qun Yan; Annelie Brauner; Kjell Tullus
Journal:  Respir Res       Date:  2002-09-05

8.  The Effect of Inhaled Budesonide on the Prevention of Chronic Lung Disease in Premature Neonates with Respiratory Distress Syndrome.

Authors:  Alireza Sadeghnia; Behzad Koorang Beheshti; Majid Mohammadizadeh
Journal:  Int J Prev Med       Date:  2018-02-08

9.  The rate and pattern of bronchopulmonary dysplasia in Kuwait.

Authors:  Mazen Al-Essa; Sitratallah O Maiyegun
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.